Evidence map›Paper›PMID 40991056›Full record

ArticleNeurogenetics2025

A novel hybrid deep learning model for segmentation and uzzy Res-LeNet based classification for Alzheimer's disease.

Soujanya R, Syamala Maganti, Sai Hanuman Akundi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurogenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Soujanya RDepartment of Computer Science and Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur District, A.P., 522302, India. soujanyar920r@gmail.com.
Syamala MagantiDepartment of Computer Science and Engineering, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur District, A.P., 522302, India.
Sai Hanuman AkundiDepartment of Computer Science and Engineering, Gokaraju Lailavathi Engineering College, Hyderabad, Telangana, 500090, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive illness that can cause behavioural abnormalities, personality changes, and memory loss. Early detection helps with future planning for both the affected person and caregivers. Thus, an innovative hybrid Deep Learning (DL) method is introduced for the segmentation and classification of AD. The classification is performed by a Fuzzy Res-LeNet model. At first, an input Magnetic Resonance Imaging (MRI) image is attained from the database. Image preprocessing is then performed by a Bilateral Filter (BF) to enhance the quality of image by denoising. Then segmentation is carried out by the proposed O-SegUNet. This method integrates the O-SegNet and U-Net model using Pearson correlation coefficient-based fusion. After the segmentation, augmentation is carried out by utilizing Synthetic Minority Oversampling Technique (SMOTE) to address class imbalance. After that, feature extraction is carried out. Finally, AD classification is performed by the Fuzzy Res-LeNet. The stages are classified as Mild Cognitive Impairment (MCI), AD, Cognitive Normal (CN), Early Mild Cognitive Impairment (EMCI), and Late Mild Cognitive Impairment (LMCI). Here, Fuzzy Res-LeNet is devised by integrating Fuzzy logic, ResNeXt, and LeNet. Furthermore, the proposed Fuzzy Res-LeNet obtained the maximum performance with an accuracy of 93.887%, sensitivity of 94.587%, and specificity of 94.008%.

Indexed as

Alzheimer DiseaseDeep LearningImage Processing, Computer-AssistedAgedBrainCognitive DysfunctionConvolutional Neural NetworksFemaleFuzzy LogicHumansMagnetic Resonance ImagingMaleAlzheimer's diseaseBilateral filterLeNetPearson correlation coefficientSegNet

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.